Arginine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Arginine: From Nutritional Supplement to Gastroparesis
One-Sentence Summary
L-Arginine is a semi-essential amino acid in the human body, widely used clinically for nutritional supplementation, metabolic support, and growth hormone stimulation testing. The TxGNN model predicts it may have therapeutic potential for gastroparesis, with a prediction score as high as 99.42%; currently, there are very few direct clinical trials supporting this direction (0 directly relevant), but there are 10 basic/animal research articles providing indirect support at the mechanism level; overall evidence is still at an early stage of research.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Nutritional supplementation / Amino acid therapy (no formal approved indication in clinical practice) |
| Predicted New Indication | Gastroparesis |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L4 (preclinical research / mechanistic research) |
| India Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
L-Arginine is the sole physiological substrate of nitric oxide synthase (NOS), which catalytically generates nitric oxide (NO) through enzymatic action. NO is the most important inhibitory neurotransmitter in the enteric nervous system, responsible for regulating receptive relaxation of the gastric fundus and relaxation of the pyloric sphincter, enabling the stomach to store food normally and empty in an orderly fashion.
One of the core pathological features of gastroparesis is the progressive loss of nitrergic neurons (nNOS+ cells), leading to insufficient NO synthesis, which in turn triggers persistent pyloric contraction and gastric emptying impairment. Against this background, arginine supplementation can increase the bioavailability of NO synthesis substrate, theoretically offering the opportunity to restore nitrergic signaling and improve gastric motility.
The most direct experimental support comes from PMID 25057793 (Reichardt et al., 2014): that study demonstrated in mice that corticosteroids (dexamethasone) can deplete L-arginine in the body and directly induce gastroparesis; L-arginine supplementation can reverse this effect. This evidence established a direct causal chain of “arginine depletion → insufficient NO → gastroparesis,” providing concrete mechanistic basis for the TxGNN prediction. However, all supporting evidence currently derives from animal models, and there are no human clinical trials directly evaluating the efficacy and safety of arginine in gastroparesis patients.
Clinical Trial Evidence
The only related trial identified in the database (NCT01702051) does not have direct relevance to arginine treatment of gastroparesis, listed below for reference:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01702051 | N/A | Unknown | 150 | An observational study assessing improvement in glycemic control following autologous pancreatic islet cell transplantation after pancreatectomy; although gastroparesis is common after total pancreatectomy and arginine stimulation testing can be used to assess islet cell function, this trial is not an intervention study of arginine for treating gastroparesis. Relevance rating: C (indirect contextual association) |
⚠️ Currently, there are no direct clinical trials using arginine as an intervention with gastroparesis as the primary endpoint.
Literature Evidence
The following literature articles are all animal studies, providing mechanisms and pathophysiological associations between arginine and gastroparesis:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25057793 | 2014 | Animal Study (Mouse) | Endocrinology | Most critical reference: Dexamethasone depletes L-arginine in mice, directly inducing gastroparesis; L-arginine supplementation can reverse this effect, establishing a direct causal relationship between arginine deficiency and gastroparesis |
| 23639814 | 2013 | Animal Study (Mouse) | Am J Physiol Gastrointest Liver Physiol | Neonatal mice deficient in tetrahydrobiopterin (BH4, an NOS cofactor) develop gastroparesis, demonstrating the association between NO synthesis pathway deficiency and gastric emptying impairment |
| 35380456 | 2022 | Animal Study (Rat) | Am J Physiol Gastrointest Liver Physiol | In the Parkinson’s disease 6-OHDA rat model, nitrergic relaxation function of the pyloric sphincter is impaired, supporting the central role of NO deficiency in gastroparesis |
| 18312542 | 2008 | Animal Study (Rat) | Neurogastroenterol Motility | Decreased nNOS expression in the jejunum of diabetic BB rats reveals the mechanism of nitrergic neuronal dysfunction in diabetic gastroparesis |
| 33867519 | 2021 | Case Report | Am J Case Reports | MELAS mitochondrial disease patients (m.3243A>G) show normalized lactate levels after lifestyle intervention; patients have gastroparesis, and arginine is a commonly used supplement for MELAS, providing indirect clinical context |
| 18322959 | 2008 | Animal Study (Mouse) | World J Gastroenterol | Evaluating the prokinetic effects of ghrelin and GHRP-6 in diabetic mouse gastroparesis, providing pharmacological comparative background |
| 19023028 | 2009 | Animal Study (Dog) | Am J Physiol Gastrointest Liver Physiol | Synchronized gastric electrical stimulation (SGES) improves gastric accommodation impairment after vagotomy through nitrergic pathways, indirectly supporting the importance of NO signaling in gastric motility regulation |
| 31984783 | 2020 | Animal Study (Rat) | Am J Physiol Gastrointest Liver Physiol | Sacral nerve stimulation (SNS) improves gastric accommodation through spinal afferent and vagal efferent pathways, providing neuromodulation context |
| 21193530 | 2011 | Animal Study (Rat) | Am J Physiol Gastrointest Liver Physiol | Hyperglycemia inhibits gastric motility through KATP channels in the celiac ganglia, elucidating the neural mechanism of diabetic gastroparesis |
| 8194696 | 1994 | Animal Study (Rat) | Gastroenterology | Food protein-induced allergic response causes delayed gastric emptying in rats, exploring the immunopathological mechanism of gastroparesis |
India Market Information
According to available information, L-Arginine currently has no registered pharmaceutical license in India, and market status is “Not marketed.”
Note: Arginine is widely available in the market as a dietary supplement, but formal approval data for prescription drug indications have not yet been included in this database. It is recommended to check the official CDSCO database separately to confirm the registration status of supplements and raw materials.
Safety Considerations
Currently, safety data (including warnings, contraindications, and drug interactions) have not been completely compiled. Please refer to warnings and precautions in the product labeling.
Special reminder: The safety of arginine in specific situations (such as severe hepatic dysfunction or sepsis patients) requires individual assessment; high-dose intravenous injection of arginine hydrochloride may cause hyperchloremic acidosis; complete safety data should be confirmed before use.
Conclusion and Next Steps
Decision: Hold
Rationale: Current evidence only reaches L4 (preclinical animal research). Although the mechanistic hypothesis demonstrates logical consistency (NO substrate supplementation → nitrergic signal recovery → improved gastric motility), it lacks human trial data, and the drug has no market approval history in India; furthermore, there are critical gaps in the safety database, such that conditions are not met to advance toward clinical application.
To proceed, the following is needed:
- Complete safety data: Query CDSCO labeling and complete DrugBank drug information to confirm warnings, contraindications, and drug interactions (currently all are Data Gaps, classified as Blocking level)
- Mechanism of action documentation: Obtain formal DrugBank mechanistic data and complete mechanism of action analysis
- Proof-of-concept study design: Design Phase 1/2 exploratory trials in gastroparesis patients evaluating the effect of L-arginine supplementation (oral or intravenous) on gastric emptying rate (gastric emptying scintigraphy)
- Target population definition: Prioritize arginine deficiency-related populations, such as MELAS patients (m.3243A>G), chronic corticosteroid users, or diabetic gastroparesis patients in whom nNOS activity can be measured
- Biomarker strategy: Explore the feasibility of plasma L-arginine concentration and NO metabolites (nitrate/nitrite) as surrogate efficacy endpoints
- India market regulatory assessment: Confirm the regulatory pathway for arginine as a prescription drug in India and current market status
⚠️ Disclaimer: This report is a research summary of TxGNN model prediction results provided for academic research reference only and does not constitute medical advice. Repurposing candidate indications must undergo rigorous clinical validation before application to patients.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.